Therapeutic Advantage of Targeting PRMT5 in Combination with Chemotherapies or EGFR/HER2 Inhibitors in Triple-Negative Breast CancersRayan Dakroub, Thierry Dubois|Breast Cancer Targets and Therapy|2023Cited by 8